Sizing Up The Competition In BTK Inhibition
This article was originally published in Pharmaceutical Approvals Monthly
Celgene’s latest Phase I dose-ranging data for the BTK inhibitor CC-292 show better response rates than before. The BTK target has become highly attractive, yet the competitive landscape for this particular class still looks sparse, with four drugs in the clinic and two slated for INDs in 2014.
You may also be interested in...
Companies developing new drugs for CLL build pipelines that will allow experimentation with a variety of combinations and look to position their candidates as the backbone for treatment in the space.
Future usage of new drugs depends on label expansion into a range of lymphomas.
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.